It may slow some of the biological processes associated with aging
In a carefully controlled clinical trial at UC San Diego, the widely prescribed GLP-1 drug semaglutide revealed an unexpected capacity: it appears to slow the biological processes of aging itself, not merely the symptoms we associate with it. Measuring chemical marks on DNA across 108 adults living with HIV, researchers found a 9 percent deceleration in the pace of biological aging over 32 weeks—a signal spanning inflammation, organ health, and mortality risk. Because HIV accelerates aging's familiar mechanisms in ways that mirror, only earlier and more severely, what happens in all of us, this population offers a rare window into interventions that may one day extend healthy life more broadly. The question humanity now carries forward is whether a drug born to manage weight and blood sugar might also be a key to the older, deeper problem of how we age.
- A drug already reshaping how the world thinks about obesity and diabetes has now produced the first randomized evidence that it may slow biological aging at the DNA level.
- The urgency is sharpened by the population studied: adults with HIV age faster even under viral control, making the biological clock a pressing clinical problem, not a distant abstraction.
- Epigenetic clocks measuring inflammation, organ function, and mortality risk all pointed in the same direction—semaglutide was slowing the accumulation of aging's molecular fingerprints across multiple body systems simultaneously.
- A companion study added weight to the signal, finding that nearly half of participants grew longer telomeres—the chromosomal caps that erode with age—and those individuals also walked faster, suggesting the biology translated into real physical gains.
- Researchers are tempering enthusiasm carefully: this is a slowdown, not a reversal, and larger trials must confirm how long the effect holds, at what dose, and whether pairing the drug with diet and exercise amplifies the benefit.
- The Stein Institute for Research on Aging is already moving to convert these findings into personalized aging dashboards for clinical use, signaling that the field is treating this not as a curiosity but as a foundation to build upon.
Semaglutide, the GLP-1 drug that reshaped conversations about weight loss and diabetes, may be doing something far more fundamental: slowing the biological clock itself. Researchers at UC San Diego have published the first randomized, placebo-controlled evidence that the drug decelerates the accumulation of aging markers in human DNA—at least in adults living with HIV.
The trial enrolled 108 people with HIV-associated lipohypertrophy, a condition causing abnormal fat accumulation around the abdomen and organs. Half received weekly semaglutide injections for 32 weeks; the other half received placebo. Using epigenetic clocks—tools that track chemical methylation patterns on DNA to measure how quickly cells are aging—researchers found that semaglutide slowed the overall pace of biological aging by 9 percent. The effect appeared not in one system but across clocks measuring inflammation, blood health, and the function of the brain, heart, kidneys, liver, and metabolism.
Lead author Michael Corley explained the likely mechanism: semaglutide reduces chronic inflammation and metabolic stress, both primary engines of premature aging in people with HIV. It also shrinks the dangerous visceral fat that accumulates around organs, dampening the inflammatory signals that accelerate cellular aging. Emerging evidence suggests the drug may also reprogram cells across different organ systems, which could explain the breadth of the effect.
A companion study reinforced the findings. In people with HIV and fatty liver disease, 42 percent showed reduced biological aging after 24 weeks, and nearly half grew longer telomeres—the protective chromosomal caps that shorten naturally with age. Those individuals also walked faster after treatment, suggesting the molecular changes translated into genuine physical improvement.
Corley was measured in his conclusions: the drug slows certain aging processes; it does not reverse them or make people younger. But the implications extend well beyond HIV. Because this population experiences accelerated versions of the same aging mechanisms present in everyone, it offers a valuable testing ground for interventions aimed at extending healthy, functional life more broadly.
Larger trials are needed to confirm the findings, establish optimal dosing, and determine whether combining semaglutide with lifestyle changes like diet and exercise amplifies the effect. The Stein Institute for Research on Aging is already planning personalized aging dashboards to help clinicians track biological age in individual patients. The deeper question now is whether GLP-1 drugs might become tools not just for managing metabolic disease, but for slowing the fundamental biology of aging itself.
Semaglutide, the GLP-1 drug that has become synonymous with weight loss and blood sugar control, appears to do something else entirely: it may slow the biological clock itself. Researchers at UC San Diego have published the first randomized, placebo-controlled evidence that this widely prescribed medication actually decelerates the accumulation of aging markers in human DNA—at least in adults living with HIV.
The finding emerged from a careful analysis of a 32-week clinical trial involving 108 people with HIV-associated lipohypertrophy, a condition in which fat accumulates abnormally around the abdomen and organs. Half received weekly semaglutide injections; the other half received placebo. The researchers used epigenetic clocks—biological tools that measure chemical marks on DNA called methylation patterns—to track whether cells were aging faster or slower under treatment. These marks don't alter the genetic code itself, but they regulate which genes turn on and off, and they shift predictably as people age.
The results were striking. Compared to placebo, people treated with semaglutide showed a broad slowdown in biological aging across multiple epigenetic clocks. The drug slowed the overall pace of aging by 9 percent, as measured by one prominent clock called DunedinPACE. Another clock, PCGrimAge, which tracks biological processes linked to mortality risk and age-related disease, showed significant slowing as well. The effect wasn't confined to one measure or one organ system—it appeared across clocks measuring inflammation, blood health, brain, heart, kidney, liver, and metabolic function.
Michael Corley, the study's lead author and an associate professor at UC San Diego's School of Medicine, explained the likely mechanism. People with HIV experience accelerated aging even when their virus is well-controlled by antiretroviral drugs. Semaglutide appears to interrupt this process by reducing chronic inflammation and metabolic stress, both primary drivers of premature aging in this population. The drug also shrinks visceral and ectopic fat—the dangerous fat that accumulates around organs—which in turn dampens the inflammatory and metabolic signals that fuel aging at the cellular level. Emerging evidence suggests semaglutide may also reprogram cells in different organs, which could explain why the aging slowdown appears across so many biological systems.
A companion study published in a separate journal found similar patterns in people with HIV and fatty liver disease. Over 24 weeks of semaglutide treatment, 42 percent of participants showed reduced biological aging as measured by DunedinPACE, and those who improved also had greater reductions in liver fat. Nearly half the participants showed lengthened telomeres—the protective caps on chromosomes that naturally shorten with age—and those individuals also walked faster after treatment, suggesting real improvements in physical function.
Corley was careful to temper expectations. "We are not saying that semaglutide reverses aging or makes people younger," he said. The signal is more modest: the drug may slow some of the biological processes that drive aging. But the implications reach beyond HIV treatment. Many of the aging mechanisms the researchers studied in this population are central to aging in everyone. Because these processes emerge earlier or more severely in people with HIV, this community can serve as a testing ground for interventions that might improve healthspan—the years of healthy, functional life—across the broader population.
Larger clinical trials will be needed to confirm these findings, determine how long the effects persist, and establish optimal dosing. Future research will also test whether semaglutide's effects on aging biology are amplified when combined with lifestyle changes like diet, exercise, and better sleep. The Stein Institute for Research on Aging is already planning to translate these results into personalized "aging dashboards" that would allow clinicians to track biological aging in individual patients and design targeted therapies. The question now is whether this class of drugs—GLP-1 receptor agonists—might offer a tool not just for managing weight and blood sugar, but for slowing the fundamental biological processes that make us age.
Citações Notáveis
We are not saying that semaglutide reverses aging or makes people younger. What we are seeing is a signal that it may slow some of the biological processes associated with aging.— Michael Corley, UC San Diego School of Medicine
Many of the biological processes we study in HIV are also central to aging in the general population. Because these processes can emerge earlier or be more pronounced in people with HIV, this community can help us identify interventions that may improve healthspan more broadly.— Michael Corley, UC San Diego School of Medicine
A Conversa do Hearth Outra perspectiva sobre a história
So these epigenetic clocks—they're not measuring actual time passing. They're measuring something about the cells themselves?
Exactly. They're reading chemical marks on DNA that shift in predictable patterns as we age. Think of them as biological scorecards. The marks don't change your genes, but they change how your genes behave. And semaglutide seemed to slow down how fast those marks were accumulating.
And this matters because people with HIV age faster than they should, even when the virus is controlled?
Right. That's the crucial context. Their immune systems stay chronically activated even on good antiretroviral therapy. That constant low-level inflammation and metabolic stress accelerates aging at the cellular level. Semaglutide appears to quiet that down.
By reducing fat around the organs?
That's part of it. But also by directly reducing inflammation and metabolic stress. The fat itself is inflammatory—it sends out signals that age cells faster. Remove it, and you remove one of the aging accelerators.
Did everyone in the study benefit equally?
No. In the companion study with fatty liver disease, only 42 percent showed slowed aging by one measure, and 34 percent by another. So there's real variation. Some people responded, others didn't. That's why they need bigger trials—to figure out who benefits most and why.
What happens when you stop taking it?
That's one of the big open questions. We don't know if the effects persist or fade. We don't know the optimal dose or how long you'd need to take it. Those are the next experiments.
And the broader population—why should someone without HIV care about this?
Because the aging mechanisms they're studying in HIV are universal. Inflammation, metabolic dysfunction, visceral fat—these drive aging in everyone. If semaglutide can slow aging in a population where it's accelerated, it might slow it in the general population too. That's the hypothesis they're testing next.